Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis

Pediatric Rheumatology international Trials Organization, the Childhood arthritis &Rheumatology Research alliance, the Pediatric Rheumatology Collaborative study Group and the Histiocyte society, Francesca Minoia, Francesca Bovis, Sergio Davì, Anna Carin Horne, Michel Fischbach, Michael Frosch, Adam Huber, Marija Jelusic, Sujata Sawhney, Deborah K. McCurdy, Clóvis A. Silva, Donato Rigante, Erbil Unsal, Nicolino Ruperto, Alberto Martini, Randy Q. Cron, Angelo Ravelli

Research output: Contribution to journalArticle

Abstract

Objective To develop and validate a diagnostic score that aids in identifying macrophage activation syndrome (MAS) in patients with systemic juvenile idiopathic arthritis (sJIA). Methods The clinical and laboratory features of 362 patients with sJIA-associated MAS and 404 patients with active sJIA without evidence of MAS were collected in a multinational collaborative project. Eighty percent of the study population was used to develop the score and the remaining 20% constituted the validation sample. A Bayesian Model Averaging approach was used to assess the role of each clinical and laboratory variables in the diagnosis of MAS and to obtain the coefficients of selected variables. The final score, named MAS/sJIA (MS) score, resulted from the linear combination of these coefficients multiplied by the values of each variable. The cut-off that best discriminated MAS from active sJIA was calculated by means of receiver operating characteristic (ROC) curve analysis. Score performance was evaluated in both developmental and validation samples. Results The MS score ranges from-8.4 to 41.8 and comprises seven variables: central nervous system dysfunction, haemorrhagic manifestations, active arthritis, platelet count, fibrinogen, lactate dehydrogenase and ferritin. A cut-off value ≥-2.1 revealed the best performance in discriminating MAS from active sJIA, with a sensitivity of 0.85, a specificity of 0.95 and a kappa value of 0.80. The good performance of the MS score was confirmed in the validation sample. Conclusion The MS score is a powerful and feasible tool that may assist practitioners in making a timely diagnosis of MAS in patients with sJIA.

Original languageEnglish
Pages (from-to)1357-1362
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume78
Issue number10
DOIs
Publication statusPublished - Jan 1 2019

Keywords

  • diagnostic score
  • hemophagocytic syndrome
  • macrophage activation syndrome
  • still's disease
  • systemic juvenile idiopathic arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis'. Together they form a unique fingerprint.

  • Cite this

    Pediatric Rheumatology international Trials Organization, the Childhood arthritis &Rheumatology Research alliance, the Pediatric Rheumatology Collaborative study Group and the Histiocyte society, Minoia, F., Bovis, F., Davì, S., Horne, A. C., Fischbach, M., Frosch, M., Huber, A., Jelusic, M., Sawhney, S., McCurdy, D. K., Silva, C. A., Rigante, D., Unsal, E., Ruperto, N., Martini, A., Cron, R. Q., & Ravelli, A. (2019). Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 78(10), 1357-1362. https://doi.org/10.1136/annrheumdis-2019-215211